^
Association details:
Biomarker:No biomarker
Cancer:Lung Non-Small Cell Squamous Cancer
Drug:Tevimbra (tislelizumab-jsgr) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Title:

China National Medical Products Administration Approves Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer

Published date:
01/13/2021
Excerpt:
BeiGene, Ltd...today announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration (NMPA) for use in combination with two chemotherapy regimens as a first-line treatment for patients with advanced squamous non-small cell lung cancer (NSCLC).
Secondary therapy:
Chemotherapy
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial

Published date:
04/01/2021
Excerpt:
After a median study follow-up of 8.6 months (95% CI, 8.1-9.0 months), IRC-assessed PFS was significantly improved with tislelizumab plus chemotherapy (arm A, 7.6 months; arm B, 7.6 months) vs chemotherapy alone...adding tislelizumab to chemotherapy was associated with significantly prolonged IRC-assessed PFS, higher IRC-assessed ORRs...
Secondary therapy:
carboplatin + paclitaxel
DOI:
10.1001/jamaoncol.2021.0366
Trial ID: